Current Gastroenterology Reports

, Volume 8, Issue 6, pp 499–505 | Cite as

Insights in immunomodulatory therapies for ulcerative colitis and Crohn’s disease

  • Geoffrey C. Nguyen
  • Mary L. Harris
  • Themistocles Dassopoulos


Immunomodulators are a class of drugs that attenuate the underlying inflammatory processes of Crohn’s disease (CD) and ulcerative colitis (UC), the two major inflammatory bowel diseases (IBD). These agents play a prominent role in the management of refractory and steroid-dependent IBD. The immunomodulatory drugs in the IBD arsenal include azathioprine, 6-mercaptopurine, methotrexate, cyclosporine, and tacrolimus. Azathioprine and 6-mercaptopurine are considered firstline immunosuppressants due to their proven efficacy in both CD and UC and their safety profile, whereas cyclosporine occupies a niche as a surgery-sparing agent in the acute management of severe, steroid-refractory UC. Immunomodulators also appear to have a role as adjunctive therapy when used with infliximab or other biologic agents to reduce immunogenicity. Although data have been limited to observational studies, azathioprine and 6-mercaptopurine may be used during pregnancy.

References and Recommended Reading

  1. 1.
    D’Haens GR, Hommes D, Baert F, et al.: A combined regimen of infliximab and azathioprine induces better endoscopic healing than classic step-up therapy in newly diagnosed Crohn’s disease. Gastroenterology 2006, 130:A110.Google Scholar
  2. 2.
    Hommes D, Baert F, van Assche G, et al.: The ideal management of Crohn’s disease: top down versus step up strategies, a randomized controlled trial. Gastroenterology 2006, 130:A108.Google Scholar
  3. 3.
    Poppe D, Tiede I, Fritz G, et al.: Azathioprine suppresses ezrin-radixin-moesin-dependent T cell-APC conjugation through inhibition of Vav guanosine exchange activity on Rac proteins. J Immunol 2006, 176:640–51.PubMedGoogle Scholar
  4. 4.
    Lichtenstein GR, Abreu MT, Cohen R, et al.: American Gastroenterological Association Institute technical review on corticosteroids, immunomodulators, and infliximab in inflammatory bowel disease. Gastroenterology 2006, 130:940–987.PubMedCrossRefGoogle Scholar
  5. 5.
    Ardizzone S, Maconi G, Russo A, et al.: Randomised controlled trial of azathioprine and 5-aminosalicylic acid for treatment of steroid dependent ulcerative colitis. Gut 2006, 55:47–53. This study is an important and long-awaited trial with wellde fined endpoints that demonstrates the role of AZA in the maintenance of UC.PubMedCrossRefGoogle Scholar
  6. 6.
    Hanauer SB, Korelitz BI, Rutgeerts P, et al.: Postoperative maintenance of Crohn’s disease remission with 6-mercaptopurine, mesalamine, or placebo: a 2-year trial. Gastroenterology 2004, 127:723–729.PubMedCrossRefGoogle Scholar
  7. 7.
    Ardizzone S, Maconi G, Sampietro GM, et al.: Azathioprine and mesalamine for prevention of relapse after conservative surgery for Crohn’s disease. Gastroenterology 2004, 127:730–740.PubMedCrossRefGoogle Scholar
  8. 8.
    Cosnes J, Nion-Larmurier I, Beaugerie L, et al.: Impact of the increasing use of immunosuppressants in Crohn’s disease on the need for intestinal surgery. Gut 2005, 54:237–241.PubMedCrossRefGoogle Scholar
  9. 9.
    Dubinsky MC: Azathioprine, 6-mercaptopurine in inflammatory bowel disease: pharmacology, efficacy, and safety. Clin Gastroenterol Hepatol 2004, 2:731–743. This article provides an excellent review of AZA metabolism and optimization of thiopurine therapy.PubMedCrossRefGoogle Scholar
  10. 10.
    Lichtenstein GR, Abreu MT, Cohen R, et al.: American Gastroenterological Association Institute medical position statement on corticosteroids, immunomodulators, and infliximab in inflammatory bowel disease. Gastroenterology 2006, 130:935–939.PubMedCrossRefGoogle Scholar
  11. 11.
    Cuffari C, Dassopoulos T, Turnbough L, et al.: Thiopurine methyltransferase activity influences clinical response to azathioprine in inflammatory bowel disease. Clin Gastroenterol Hepatol 2004, 2:410–417. This study provides novel insight into the role of TPMT in the clinical response to the thiopurines.PubMedCrossRefGoogle Scholar
  12. 12.
    Sparrow MP, Hande SA, Friedman S, et al.: Allopurinol safely and effectively optimizes tioguanine metabolites in inflammatory bowel disease patients not responding to azathioprine and mercaptopurine. Aliment Pharmacol Ther 2005, 22:441–446.PubMedCrossRefGoogle Scholar
  13. 13.
    Sparrow M, Hande SA, Friedman S, et al.: Optimization of 6-thioguanine production by allopurinol in inflammatory bowel disease patients not responding to azathioprine/6-mercaptopurine leads to improved disease activity, reduced corticosteroid requirements and normalization of liver enzymes. Gastroenterology 2006, 130:A142.Google Scholar
  14. 14.
    Teml A, Schwab M, Harrer M, et al.: A prospective, open-label trial of 6-thioguanine in patients with ulcerative or indeterminate colitis. Scand J Gastroenterol 2005, 40:1205–1213.PubMedCrossRefGoogle Scholar
  15. 15.
    Dubinsky MC, Vasiliauskas EA, Singh H, et al.: 6-thioguanine can cause serious liver injury in inflammatory bowel disease patients. Gastroenterology 2003, 125:298–303.PubMedCrossRefGoogle Scholar
  16. 16.
    Osterman MT, Kundu R, Lichtenstein GR, et al.: Association of 6-thioguanine nucleotide levels and inflammatory bowel disease activity: a meta-analysis. Gastroenterology 2006, 130:1047–1053.PubMedCrossRefGoogle Scholar
  17. 17.
    Neurath MF, Kiesslich R, Teichgraeber U, et al.: Prediction of azathioprine responsiveness in Crohn’s disease by 6-thioguanosine di- and triphosphate levels in red blood cells: a prospective study. Gastroenterology 2006, 130:A84.Google Scholar
  18. 18.
    Lemann M, Mary JY, Colombel JF, et al.: A randomized, double-blind, controlled withdrawal trial in Crohn’s disease patients in long-term remission on azathioprine. Gastroenterology 2005, 128:1812–1818. This important study demonstrates the advantage of continuing AZA maintenance therapy beyond 3.5 years of remission and has significant implications for clinical practice.PubMedCrossRefGoogle Scholar
  19. 19.
    Alfadhli AA, McDonald JW, Feagan BG. Methotrexate for induction of remission in refractory Crohn’s disease. Cochrane Database Syst Rev 2005, CD003459.Google Scholar
  20. 20.
    Ardizzone S, Bollani S, Manzionna G, et al.: Comparison between methotrexate and azathioprine in the treatment of chronic active Crohn’s disease: a randomised, investigatorblind study. Dig Liver Dis 2003, 35:619–627.PubMedCrossRefGoogle Scholar
  21. 21.
    van DierenJM, Kuipers EJ, Samsom JN, et al.: Revisiting the immunomodulators tacrolimus, methotrexate, and mycophenolate mofetil: their mechanisms of action and role in the treatment of IBD. Inflamm Bowel Dis 2006, 12:311–327.PubMedCrossRefGoogle Scholar
  22. 22.
    Herrlinger KR, Cummings JR, Barnardo MC, et al.: The pharmacogenetics of methotrexate in inflammatory bowel disease. Pharmacogenet Genomics 2005, 15:705–711.PubMedCrossRefGoogle Scholar
  23. 23.
    Schreiber SL, Crabtree GR. The mechanism of action of cyclosporin A and FK506. Immunol Today 1992, 13:136–142.PubMedCrossRefGoogle Scholar
  24. 24.
    Lichtiger S, Present DH, Kornbluth A, et al.: Cyclosporine in severe ulcerative colitis refractory to steroid therapy. N Engl J Med 1994, 330:1841–1845.PubMedCrossRefGoogle Scholar
  25. 25.
    D’Haens G, Lemmens L, Geboes K, et al.: Intravenous cyclosporine versus intravenous corticosteroids as single therapy for severe attacks of ulcerative colitis. Gastroenterology 2001, 120:1323–1329.PubMedCrossRefGoogle Scholar
  26. 26.
    van AsscheG, D’Haens G, Noman M, et al.: Randomized, double-blind comparison of 4 mg/kg versus 2 mg/kg intravenous cyclosporine in severe ulcerative colitis. Gastroenterology 2003, 125:1025–1031. This paper provides evidence supporting the efficacy of lower doses and target ranges for cyclosporine and has high clinical impact.PubMedCrossRefGoogle Scholar
  27. 27.
    McDonald JW, Feagan BG, Jewell D, et al.: Cyclosporine for induction of remission in Crohn’s disease. Cochrane Database Syst Rev 2005, CD000297.Google Scholar
  28. 28.
    Ogata H, Matsui T, Nakamura M, et al.: A randomised, dose-finding study of oral tacrolimus (FK506) therapy in refractory ulcerative colitis. Gut 2006, 55:1255–1262.PubMedCrossRefGoogle Scholar
  29. 29.
    Sandborn WJ, Present DH, Isaacs KL, et al.: Tacrolimus for the treatment of fistulas in patients with Crohn’s disease: a randomized, placebo-controlled trial. Gastroenterology 2003, 125:380–388.PubMedCrossRefGoogle Scholar
  30. 30.
    Baumgart DC, Pintof. JP, Sturm A, et al.: Tacrolimus is safe and effective in patients with severe steroid-refractory or steroid-dependent inflammatory bowel disease: a longterm follow-up. Am J Gastroenterol 2006, 101:1048–1056.PubMedCrossRefGoogle Scholar
  31. 31.
    Neurath MF, Wanitschke R, Peters M, et al.: Randomised trial of mycophenolate mofetil versus azathioprine for treatment of chronic active Crohn’s disease. Gut 1999, 44:625–628.PubMedCrossRefGoogle Scholar
  32. 32.
    Orth T, Peters M, Schlaak JF, et al.: Mycophenolate mofetil versus azathioprine in patients with chronic active ulcerative colitis: a 12-month pilot study. Am J Gastroenterol 2000, 95:1201–1207.PubMedCrossRefGoogle Scholar
  33. 33.
    Farrell RJ, Alsahli M, Jeen YT, et al.: Intravenous hydrocortisone premedication reduces antibodies to infliximab in Crohn’s disease: a randomized controlled trial. Gastroenterology 2003, 124:917–924.PubMedCrossRefGoogle Scholar
  34. 34.
    Lemann M, Mary JY, Duclos B, et al.: Infliximab plus azathioprine for steroid-dependent Crohn’s disease patients: a randomized placebo-controlled trial. Gastroenterology 2006, 130:1054–1061.PubMedCrossRefGoogle Scholar
  35. 35.
    Hanauer SB, Feagan BG, Lichtenstein GR, et al., for theACCENT I Study Group: Maintenance infliximab for Crohn’s disease: the ACCENT I randomised trial. Lancet 2002, 359:1541–1549.PubMedCrossRefGoogle Scholar
  36. 36.
    Maini RN, Breedveld FC, Kalden JR, et al.: Sustained improvement over two years in physical function, structural damage, and signs and symptoms among patients with rheumatoid arthritis treated with infliximab and methotrexate. Arthritis Rheum 2004, 50:1051–1065.PubMedCrossRefGoogle Scholar
  37. 37.
    van AsscheG, Paintaud G, D’ HG, et al.: Continuation of immunomodulators is not required to maintain adequate infliximab efficacy in patients with Crohn’s disease but may improve pharmacokinetics. Gastroenterology 2006, 130:A142.Google Scholar
  38. 38.
    Panaccione R, Hanauer SB, Fedorak R, et al.: Concomitant immunosuppressive and adalimumab therapy in patients with Crohn’s disease. Gastroenterology 2006, 130:A479.Google Scholar
  39. 39.
    Mantzaris GJ, Sfakianakis M, Archavlis E, et al.: A prospective randomized observer-blind 2-year trial of azathioprine monotherapy versus azathioprine and olsalazine for the maintenance of remission of steroid-dependent ulcerative colitis. Am J Gastroenterol 2004, 99:1122–1128.PubMedCrossRefGoogle Scholar
  40. 40.
    Hande S, Wilson-Rich N, Bousvaros A, et al.: 5-aminosalicylate therapy is associated with higher 6-thioguanine levels in adults and children with inflammatory bowel disease in remission on 6-mercaptopurine or azathioprine. Inflamm Bowel Dis 2006, 12:251–257.PubMedCrossRefGoogle Scholar
  41. 41.
    Kandiel A, Fraser AG, Korelitz BI, et al.: Increased risk of lymphoma among inflammatory bowel disease patients treated with azathioprine and 6-mercaptopurine. Gut 2005, 54:1121–1125.PubMedCrossRefGoogle Scholar
  42. 42.
    Disanti W, Rajapakse RO, Korelitz BI, et al.: Incidence of neoplasms in patients who develop sustained leukopenia during or after treatment with 6-mercaptopurine for inflammatory bowel disease. Clin Gastroenterol Hepatol 2006, 4:1025–1029.PubMedCrossRefGoogle Scholar
  43. 43.
    Lewis JD, Schwartz JS, Lichtenstein GR: Azathioprine for maintenance of remission in Crohn’s disease: benefits outweigh the risk of lymphoma. Gastroenterology 2000, 118:1018–24.PubMedCrossRefGoogle Scholar
  44. 44.
    Navarro JT, Ribera JM, Mate JL, et al.: Hepatosplenic T-gammadelta lymphoma in a patient with Crohn’s disease treated with azathioprine. Leuk Lymphoma 2003, 44:531–533.PubMedCrossRefGoogle Scholar
  45. 45.
    Thayu M, Markowitz JE, Mamula P, et al.: Hepatosplenic T-cell lymphoma in an adolescent patient after immunomodulator and biologic therapy for Crohn disease. J Pediatr Gastroenterol Nutr 2005, 40:220–222.PubMedCrossRefGoogle Scholar
  46. 46.
    Lichtenstein GR, Cohen RD, Feagan BG, et al.: Safety of infliximab and other Crohn’s disease therapies — TREAT registry data with nearly 15,000 patient-years of follow-up. Gastroenterology 2006, 130, 4(Supp 2):A71.Google Scholar
  47. 47.
    Kane SV, Khatibi B, Reddy D: Use of immunosuppressants results in a higher incidence of abnormal Pap smears in women with inflammatory bowel disease (IBD). Gastroenterology 2006, 130:A2.Google Scholar
  48. 48.
    Colombel JF, Loftus EV, Jr, Tremaine WJ, et al.: Early postoperative complications are not increased in patients with Crohn’s disease treated perioperatively with infliximab or immunosuppressive therapy. Am J Gastroenterol 2004, 99:878–883.PubMedCrossRefGoogle Scholar
  49. 49.
    Subramanian V, Pollok RC, Kang JY, et al.: Systematic review of postoperative complications in patients with inflammatory bowel disease treated with immunomodulators. Br J Surg 2006, 93:793–799.PubMedCrossRefGoogle Scholar
  50. 50.
    Norgard B, Pedersen L, Fonager K, et al.: Azathioprine, mercaptopurine and birth outcome: a population-based cohort study. Aliment Pharmacol Ther 2003, 17:827–834.PubMedCrossRefGoogle Scholar
  51. 51.
    Francella A, Dyan A, Bodian C, et al.: The safety of 6-mercaptopurine for childbearing patients with inflammatory bowel disease: a retrospective cohort study. Gastroenterology 2003, 124:9–17. This paper describes the largest series of pregnant women with IBD who have undergone 6-MP therapyPubMedCrossRefGoogle Scholar
  52. 52.
    Bar OB, Hackman R, Einarson T, et al.: Pregnancy outcome after cyclosporine therapy during pregnancy: a meta-analysis. Transplantation 2001, 71:1051–1055.CrossRefGoogle Scholar
  53. 53.
    Baumgart DC, Sturm A, Wiedenmann B, et al.: Uneventful pregnancy and neonatal outcome with tacrolimus in refractory ulcerative colitis. Gut 2005, 54:1822–1823PubMedCrossRefGoogle Scholar

Copyright information

© Current Science Inc 2006

Authors and Affiliations

  • Geoffrey C. Nguyen
  • Mary L. Harris
  • Themistocles Dassopoulos
    • 1
  1. 1.Division of GastroenterologyThe Johns Hopkins HospitalBaltimoreUSA

Personalised recommendations